Additionally, the treatment protocol significantly upended the critical compensatory signaling markers such as PDX-1, Ki67, TUNEL, BCL-2, c-myc, and PI3K/Akt1/mTOR; hypoxia markers such as HIF-1α, HIF-2α, CAIX and pimonidazole; the EMT markers such as N- and E-cadherins, EpCAM, and vimentin; and CSC markers such as CD36, CD44, CD24, CXCR4, ALDH1, and ABCG2 in a mouse model of human pancreatic cancer. This evidence concerns the gene PDX1 and familial pancreatic carcinoma.